GHR Peptide-6 Evidence Guide
Evidence for GHR Peptide-6 is too preliminary to support a research protocol with confidence. Published data is extremely limited, with no independent replication and no clinical trials. Of the Healing & Recovery compounds in this library, BPC-157 or thymosin beta-4 have substantially more preclinical evidence as starting points.
Our Take
Evidence for GHR Peptide-6 is too preliminary to support a research protocol with confidence. Published data is extremely limited, with no independent replication and no clinical trials. Of the Healing & Recovery compounds in this library, BPC-157 or thymosin beta-4 have substantially more preclinical evidence as starting points.
- Best for
- No validated application at this stage
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Chronic Wound Healing: Level D, mostly non-human evidence - Animal studies using diabetic wound models show accelerated wound closure, increased granulation tissue formation, and improved epithelialization compared to control groups.
- Burn Injury Recovery: Level D, mostly non-human evidence - Limited preclinical data suggests improved healing in burn wound models, with enhanced collagen deposition and reduced inflammatory infiltrate.
Side Effects and Warnings
- Limited safety data available
- Possible local irritation at application site
- Potential appetite stimulation (shared with GHRP-6)
- Theoretical cortisol and prolactin elevation
- Not approved for clinical use in any country
- Evidence base is limited and primarily from a single research group
- Relationship to GHRP-6 may carry similar endocrine side effects at systemic doses
- Long-term safety profile is unknown
Research Dosage References
- <strong>Topical (wound application)</strong> - 200-400 mcg per cm2 wound area - Daily or every other day - Applied directly to wound bed in preclinical studies, often in hydrogel or cream formulation.
- <strong>Subcutaneous (perilesional)</strong> - 100-300 mcg - Daily - Injected around the wound periphery in some animal study protocols.
Mechanism of Action
GHR Peptide-6 promotes wound healing through: 1. Angiogenesis stimulation: Upregulates vascular endothelial growth factor (VEGF) expression, promoting new blood vessel formation in wound beds. 2. Fibroblast proliferation: Directly stimulates fibroblast migration and proliferation, enhancing granulation tissue formation. 3. Anti-inflammatory modulation: Reduces pro-inflammatory cytokine levels in the wound microenvironment, shifting toward a reparative phase. 4. Collagen synthesis: Increases type I and type III collagen deposition, improving wound tensile strength during the remodeling phase.
Legal Status
GHR Peptide-6 wound healing variant is a research compound. Not approved for clinical use. GHRP-6 and its analogs are classified as research chemicals in most jurisdictions and are banned by WADA.
Primary Sources
- GHRP-6 promotes wound healing in chronic skin lesions in animal models. Growth Horm IGF Res, 2009.
- Growth hormone releasing peptide-6 enhances angiogenesis and tissue repair. J Pept Sci, 2012.
Popular Questions
- GHR Peptide-6 Benefits: Evidence, Verdict, and Limits
- GHR Peptide-6 Side Effects: Safety Signals and Warnings
- GHR Peptide-6 Research Dosage: Published Protocol Reference
- Is GHR Peptide-6 Legit? Evidence Grade and Plain-English Verdict
- GHR Peptide-6 Legal Status: Approval, Research Use, and Regulatory Notes